Home / Brands / Major Pharmaceuticals
Major Pharmaceuticals Recalls
19 recalls on record · August 1, 2018 to July 29, 2026 · Drugs
Recalls by year
18
19
26
Count of recall notices naming this brand, by the year the recall was announced. A quiet year is not proof of a safe year.
July 29, 2026DrugsFDA
Major Pharmaceuticals recalls Levothyroxine Sodium Tablets, USP, 150 mcg (0.0150 mg), 10 Tablets (10 x 1) unit dose blisters per carton, Rx only, Pack
Hazard: Subpotent Drug
July 29, 2026DrugsFDA
Major Pharmaceuticals recalls Levothyroxine Sodium Tablets, USP, 125 mcg (0.0125 mg), 10 Tablets (10 x 1) unit dose blisters per carton, Rx only, Pack
Hazard: Subpotent Drug
July 29, 2026DrugsFDA
Major Pharmaceuticals recalls Levothyroxine Sodium Tablets, USP, 75 mcg (0.075 mg), 10 Tablets (10 x 1) unit dose blisters per carton, Rx only, Packag
Hazard: Subpotent Drug
July 29, 2026DrugsFDA
Major Pharmaceuticals recalls Levothyroxine Sodium Tablets, USP, 50 mcg (0.050 mg), 10 Tablets (10 x 1) unit dose blisters per carton, Rx only, Packag
Hazard: Subpotent Drug
July 29, 2026DrugsFDA
Major Pharmaceuticals recalls Levothyroxine Sodium Tablets, USP, 25 mcg (0.025 mg), 10 Tablets (10 x 1) unit dose blisters per carton, Rx only, Packag
Hazard: Subpotent Drug
July 29, 2026DrugsFDA
Major Pharmaceuticals recalls Levothyroxine Sodium Tablets, USP, 150 mcg (0.0150 mg), 100 Tablets (10 x 10 unit dose blisters) per carton, Rx only, Pa
Hazard: Subpotent Drug
July 29, 2026DrugsFDA
Major Pharmaceuticals recalls Levothyroxine Sodium Tablets, USP, 125 mcg (0.0125 mg), 100 Tablets (10 x 10 unit dose blisters) per carton, Rx only, Pa
Hazard: Subpotent Drug
July 29, 2026DrugsFDA
Major Pharmaceuticals recalls Levothyroxine Sodium Tablets, USP, 112 mcg (0.0112 mg), 100 Tablets (10 x 10 unit dose blisters) per carton, Rx only, Pa
Hazard: Subpotent Drug
July 29, 2026DrugsFDA
Major Pharmaceuticals recalls Levothyroxine Sodium Tablets, USP, 88 mcg (0.088 mg), 100 Tablets (10 x 10 unit dose blisters) per carton, Rx only, Pack
Hazard: Subpotent Drug
July 29, 2026DrugsFDA
Major Pharmaceuticals recalls Levothyroxine Sodium Tablets, USP, 75 mcg (0.075 mg), 100 Tablets (10 x 10 unit dose blisters) per carton, Rx only, Pack
Hazard: Subpotent Drug
July 29, 2026DrugsFDA
Major Pharmaceuticals recalls Levothyroxine Sodium Tablets, USP, 50 mcg (0.050 mg), 100 Tablets (10 x 10 unit dose blisters) per carton, Rx only, Pack
Hazard: Subpotent Drug
July 29, 2026DrugsFDA
Major Pharmaceuticals recalls Levothyroxine Sodium Tablets, USP, 25 mcg (0.025 mg), 100 Tablets (10 x 10 unit dose blisters) per carton, Rx only, Pack
Hazard: Subpotent Drug
August 7, 2019DrugsFDA
MAJOR PHARMACEUTICALS recalls DIVALPROEX SODIUM EXTENDED-RELEASE TABLETS, USP Tablets, 250 mg, 100 count-unit dose carton, RX only, Manufactured by Dr
Hazard: cGMP deviations: Product was exposed above 50% relative humidity levels during packaging operations.
July 17, 2019DrugsFDA
MAJOR PHARMACEUTICALS recalls Losartan Potassium Tablets, USP. 50 mg. NDC# 0904-6390-61. Rx only. 100 count Unit Dose Cartons. Manufactured by Major P
Hazard: CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in the finished product above the interim acceptable daily intake level at the manufacturer
August 8, 2018DrugsFDA
MAJOR PHARMACEUTICALS recalls Doxycycline Hyclate Tablets, USP, 100 mg, Rx Only, 30 tablets, 3 x 10 unit dose Cartons, Mfd. by: West-Ward Pharmaceutic
Hazard: Failed Dissolution Specifications
August 1, 2018DrugsFDA
MAJOR PHARMACEUTICALS recalls Enalapril Maleate Tablets, USP, 5 mg, 100 Tablets (10 x 10) Unit Dose per carton, Rx only, Manufactured by: Wockhardt Li
Hazard: Failed Impurities/Degradation Specifications: Sub-recall because this repackaged product was recalled by the manufacturing firm, Wockhardt, due to out-of-specification results for the Enalapril DiKetopiperazine degradation product.
August 1, 2018DrugsFDA
MAJOR PHARMACEUTICALS recalls Enalapril Maleate Tablets, USP, 2.5 mg, 100 Tablets (10 x 10) Unit Dose per carton, Rx only, Manufactured by: Wockhardt
Hazard: Failed Impurities/Degradation Specifications: Sub-recall because this repackaged product was recalled by the manufacturing firm, Wockhardt, due to out-of-specification results for the Enalapril DiKetopiperazine degradation product.
August 1, 2018DrugsFDA
MAJOR PHARMACEUTICALS recalls Unit Dose Valsartan Tablets, USP. 160 mg. Rx only.,Distributed by: Major Pharmaceuticals, Livonia, MI 48152, NDC# 0904-
Hazard: CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.
August 1, 2018DrugsFDA
MAJOR PHARMACEUTICALS recalls Unit Dose Valsartan Tablets, USP, 80 mg. Rx only, Distributed by: Major Pharmaceuticals, Livonia, MI 48152, NDC# 0904-6
Hazard: CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.